Investigating the Binding Efficacy of Snake Venom Proteins as GLP-1 Analogs for Diabetes mellitus Management: An In silico Study

Objective: Diabetes mellitus (DM) is a metabolic condition defined by hyperglycemia driven insulin deficiency or decreased activity. GLP-1, gut enzyme, stimulates production and reduces hepatic glucose synthesis to regulate diabetes. GLP-1 agonists enhance sensitivity decrease blood relieve symptoms of DM. These medications represent novel paradigm manage diabetes as they improve glycaemic control in type 2 diabetic patients. Snake venom proteins have been investigated potential medicinal strategy for treatment. contain multitude bioactive constituents, such insulinotropic cytotoxins, which found influence secretion homeostasis. Methods: In the present study, snake long neurotoxin 1 Cytotoxin 7, 2a, 10 were modeled their therapeutic efficacy analogs was determined employing molecular docking techniques. The binding protein towards receptors compared against positive controls (Exenatide, Liraglutide, Semaglutide, Lixisenatide). Results: results demonstrated that cytotoxins (Cytotoxin 10) exhibited comparable with majorly interacted hydrophobic amino acids pocket receptor. toxins beneficial physicochemical properties advocated them be contender development analogs. Conclusion: Despite its outcomes, utilization agent still initial stages, additional research required assess effectiveness safety